AVEO Oncology to Present at the Canaccord Genuity 38th Annual Growth Conference
August 01 2018 - 7:00AM
Business Wire
AVEO Oncology (NASDAQ: AVEO) today announced that Michael
Bailey, president and chief executive officer, will present at the
Canaccord Genuity 38th Annual Growth Conference in Boston on
Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time.
A live webcast of the presentation can be accessed by visiting
the investors section of the Company’s website
at www.aveooncology.com. A replay of the webcast will be
archived for 30 days following the presentation date.
About AVEO
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to
advancing a broad portfolio of targeted medicines for oncology and
other areas of unmet medical need. The Company’s strategy is to
retain North American rights to its oncology portfolio while
securing partners in development and commercialization outside of
North America. The Company is working to develop and commercialize
its lead candidate tivozanib in North America as a treatment for
renal cell carcinoma. The Company has outlicensed tivozanib
(FOTIVDA®) for oncological indications in Europe and other
territories outside of North America, and it is approved in the
European Union, as well as Norway and Iceland, for the first-line
treatment of adult patients with advanced RCC and for adult
patients who are vascular endothelial growth factor receptor and
mTOR pathway inhibitor-naïve following disease progression after
one prior treatment with cytokine therapy for aRCC. The Company has
entered into partnerships to fund the development and
commercialization of AV-203 and ficlatuzumab, both clinical stage
assets in oncology. The Company is currently seeking a partner to
develop the AV-353 platform, a preclinical asset, worldwide for the
potential treatment of pulmonary arterial hypertension. The Company
previously partnered with Novartis International Pharmaceutical
Ltd. to develop the AV-380 program in cachexia and other
indications, but Novartis has notified us that it is terminating
the collaboration without cause. Accordingly, effective August 28,
2018 the Company expects to regain the rights to AV-380 and is
considering a variety of options to continue the program’s
development. For more information, please visit the Company’s
website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements
of AVEO that involve substantial risks and uncertainties.
All statements, other than statements of historical fact, contained
in this press release are forward-looking statements. Actual
results or events could differ materially due to a number of
important factors, including risks discussed in the section titled
“Risk Factors” in AVEO’s most recent Annual Report on Form 10-K,
its quarterly reports on Form 10-Q and its other filings with
the SEC. The forward-looking statements in this press release
represent AVEO’s views as of the date of this press
release. AVEO anticipates that subsequent events and
developments may cause its views to change.
While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180801005106/en/
AVEO:Argot PartnersDavid Pitts,
212-600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Sep 2023 to Sep 2024